



Dermatology Referral Form

Faxed prescriptions will only be accepted from an authorized prescriber. Prescribers are reminded patients may choose any pharmacy of their choice

1. Patient Information

Patient Name: _____ Birthdate: _____ Sex: Male Female Weight _____ Lbs. kg
 Preferred Phone: _____ Known Allergies _____
 Address: _____ City: _____ State: _____ Zip: _____


****Insurance Information: Please fax FRONT and BACK copy of ALL Insurance cards (Prescription and Medical)****

2. Prescriber Information

Prescriber Name: _____ NPI#: _____ Tax ID#: _____
 Address: _____ Phone: _____ Fax: _____
 City, State, Zip: _____ Key Contact: _____

3. Diagnosis/Clinical Information

Diagnosis: _____ ICD-10 _____
 Date of Diagnosis (or years with disease): _____
 Has patient been previously treated for this condition? Yes No
 If yes, medication/therapy failed (length of therapy): _____
 Has Patient received PPD (tuberculosis) Skin Test? Yes No
 Has Hepatitis B been ruled out or treatment been initiated? Yes No
 Does patient have a latex allergy? Yes No



_____ % BSA Affected by Psoriasis

****Please FAX recent clinical notes, labs, and tests with the prescription to expedite the Prior Authorization****

4. Prescription Information

Medication	Dose/Strength	Sig	QTY.	Refills
<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Starter Kit <input type="checkbox"/> 200 mg Prefilled Syringe <input type="checkbox"/> 200 mg Lyophilized Vial	<input type="checkbox"/> Starter Dose: 400 mg SC weeks 0, 2 and 4 <input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> 400 mg (given as 2 SC inj of 200 mg each) every other week <input type="checkbox"/> 200 mg SC every 2 weeks <input type="checkbox"/> 400 mg SC every 4 weeks	28-day supply	0
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 150 mg Prefilled Syringe <input type="checkbox"/> 300 mg Prefilled Syringe <input type="checkbox"/> 150 mg Sensoready® Pen <input type="checkbox"/> 300 mg Sensoready® Pen	<input type="checkbox"/> Starter Dose: Inject SC at weeks 0, 1, 2, 3 and 4 <input type="checkbox"/> Maintenance Dose: Inject SC every 4 weeks	28-day supply	0
<input type="checkbox"/> Dupixent®	<input type="checkbox"/> 300 mg/2ml Prefilled Syringe	<input type="checkbox"/> Starter Dose: 600 mg SC divided in 2 different injection sites <input type="checkbox"/> Maintenance dose: 300 mg SC every other week	28-day supply	0
<input type="checkbox"/> Enbrel®	<input type="checkbox"/> 50 mg/ml Mini <input type="checkbox"/> 50 mg/ml Prefilled Syringe <input type="checkbox"/> 50 mg/ml SureClick™ Autoinjector <input type="checkbox"/> 25 mg/0.5ml Prefilled Syringe	<input type="checkbox"/> Inject 50 mg SC TWICE a week <input type="checkbox"/> Inject 50 mg SC ONCE a week <input type="checkbox"/> Other: _____	28-day supply	_____
<input type="checkbox"/> Humira®	<input type="checkbox"/> 20 mg/0.1ml Citrate-Free Prefilled Syringe <input type="checkbox"/> 40 mg/0.4ml Citrate-Free Pen <input type="checkbox"/> 40 mg/0.4ml Citrate-Free Prefilled Syringe <input type="checkbox"/> Citrate-Free Starter Kit	Starter Dose: <input type="checkbox"/> Hidradenitis Suppurativa: Inject 160 mg SC in day 1, then 80 mg on day 15 <input type="checkbox"/> Plaque Psoriasis: Inject 80 mg SC day 1, then 40mg on day 8, and then 40mg every 2 weeks thereafter <input type="checkbox"/> Other: _____ Maintenance Dose: <input type="checkbox"/> Hidradenitis Suppurativa: Inject 40 mg SC on day 29 and then every week thereafter <input type="checkbox"/> Plaque Psoriasis: Inject 40 mg SC every 2 weeks	28-day supply	* 0 refills for starter dose
<input type="checkbox"/> Ilumya™	<input type="checkbox"/> 100 mg Prefilled Syringe	<input type="checkbox"/> 100 mg SC day 0 and 28, then every 12 weeks	28-day supply	_____
<input type="checkbox"/> Otezla®	<input type="checkbox"/> 4 Week Starter Pack <input type="checkbox"/> 30 mg Tablets	<input type="checkbox"/> Starter Dose: 28 Days as directed <input type="checkbox"/> Maintenance Dose: Take 1 Tablet by mouth twice daily	28-day supply	_____
<input type="checkbox"/> Siliq®	<input type="checkbox"/> 210 mg/1.5 ml Prefilled Syringe	<input type="checkbox"/> Starter Dose: 210 mg SC on weeks 0, 1, 2 <input type="checkbox"/> Maintenance Dose: 210 mg SC every 2 weeks	28-day supply	0
<input type="checkbox"/> Skyrizi®	<input type="checkbox"/> 75 mg/0.83 mL Prefilled Syringe	<input type="checkbox"/> Starter Dose: 150 mg SC at Week 0, Week 4 <input type="checkbox"/> Maintenance Dose: 150 mg SC every 12 weeks	28-day supply	_____
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45 mg/0.5 ml Prefilled Syringe <input type="checkbox"/> 90 mg/1 ml Prefilled Syringe	Starter Dose: <input type="checkbox"/> Inject 45 mg SC (patient <100 kg) at Day 1 <input type="checkbox"/> Inject 90 mg SC (patient >100 kg) at Day 1 Maintenance Dose: <input type="checkbox"/> Inject 45 mg SC (patient <100 kg) 29 days after starter dose and then every 12 weeks <input type="checkbox"/> Inject 90 mg SC (patient >100 kg) 29 days after starter dose and then every 12 weeks <input type="checkbox"/> Other: _____	28-day supply	0
<input type="checkbox"/> Taltz®	<input type="checkbox"/> Autoinjector 80 mg/mL <input type="checkbox"/> Prefilled Syringe 80 mg/mL	<input type="checkbox"/> Starter Dose: 160 mg SC at week 0; then inject 80 mg SC at weeks 2,4,6,8,10 & 12 <input type="checkbox"/> Maintenance Dose: 80 mg SC every 4 weeks	28-day supply	0
<input type="checkbox"/> Tremfya®	<input type="checkbox"/> 1 mL Prefilled Syringe	<input type="checkbox"/> Inject 100 mg SC at weeks 0, 4, and then every 8 weeks thereafter	28-day supply	_____
<input type="checkbox"/> _____				

Dispensing Options: Pick-Up | Deliver To: Patient's Home Prescriber's Office

Prescriber Signature: Prescriber, please sign and date below

Date

I authorize Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.